Alpha Tau Medical Ltd., a clinical-stage medtech company founded on proprietary alpha radiation technology, has steadily increased its R&D investment while extending its cash runway through equity raises. The company achieved a key regulatory milestone with marketing approval in Japan for treating unresectable head and neck cancer, marking progress toward global commercialization. Despite continued operating losses and significant cash burn driven by clinical trials and infrastructure expansion, strong intellectual property partnerships and collaborations underpin its strategy as it navigates the pathway from innovative therapy development to market launch.